Clinical Trial Update: A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444. [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating excretion, balance, and metabolic disposition of radiolabeled GW642444 after a single dose in chronic obstructive pulmonary disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GW642444 (GW642444)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED